All News
RheumNow Podcast - Scurvy and Mechanics (2-1-19)
Dr. Jack Cush reviews new journal articles, news reports, and more from the past week on RheumNow.com.
Read ArticleNo Difference in Oral or IV Antibiotics for Bone & Joint Infections
Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.
Read ArticleRheumNow Podcast – TNFs and the Inflammasome (1.25.19)
Dr Jack Cush reviews the news from the past week at RheumNow.com.
Read ArticleDoes Seropositivity Change with Therapy?
A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression.
Read ArticleMajor Challenges for Lupus in 2019
Despite striking improvements in survival among patients with systemic lupus erythematosus (SLE) in recent decades -- from 1-year survival of less than 50% before the introduction of prednisone to 90% today in most specialized treatment centers -- many challenges remain in this perplexing, multis
Read ArticleSmoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis
Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA.
Read ArticleAnakinra for Acute Crystal-Induced Arthritis
A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.
Read ArticleIL-6 Blocker Succeeds in Real-World Vasculitis
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Read ArticleRheumNow Podcast – Gout Spot Light (1.11.19)
Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:
Read ArticleCombo RA Treatment May Boost Risk for Serious Adverse Events
A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.
Read ArticleBMS Buyout of Celgene for $74 Billion
Reuters reports that Bristol-Myers Squibb (BMS) has announced its intention to buy Celgene Corp for nearly $74 billion in a cash-and-stock deal.
Read ArticleRheumNow Podcast – A Grand New Year (1.4.19)
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
2018 Rheumatology Year In Review
This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review. The top 10 list herein is rooted in what rheumatologists should know and what will likel
Read ArticleSevere Cutaneous Sarcoid Treated with Tofacitinib
Researchers from Yale have taken a novel approach and shown benefits when using tofacitinib in severe cutaneous sarcoidosis.
Read ArticleBest of 2018: The Safety of Paternal Exposure to DMARDs and Biologics
Pregnancy and drug safety is a complex issue, often with limited information about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.
Read ArticleBest of 2018: Ustekinumab May be Effective in Lupus
Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory param
Read ArticleBest of 2018: Unproven But Profitable Stem Cell Clinics
Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.
Read ArticleRheumNow Podcast – Rheumatologist Salaries (12.21.18)
Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.
Read ArticleReassuring VTE Data for Tofacitinib
No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.
Read ArticleH2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis
Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.
Read Article